These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31849044)

  • 1. Low-grade serous ovarian carcinoma: A comprehensive literature review.
    Goulding EA; Simcock B; McLachlan J; van der Griend R; Sykes P
    Aust N Z J Obstet Gynaecol; 2020 Feb; 60(1):27-33. PubMed ID: 31849044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
    Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
    Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study.
    Matsuo K; Machida H; Grubbs BH; Matsuzaki S; Klar M; Roman LD; Sood AK; Gershenson DM
    Gynecol Oncol; 2020 Apr; 157(1):21-28. PubMed ID: 31954535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review and meta-analysis of hormone receptor expression in low-grade serous ovarian carcinoma.
    Voutsadakis IA
    Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():172-178. PubMed ID: 33246201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in precision therapy of low-grade serous ovarian cancer: A review.
    Wang Q; Cao SH; Li YY; Zhang JB; Yang XH; Zhang B
    Medicine (Baltimore); 2024 Apr; 103(17):e34306. PubMed ID: 38669365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving population-based statistics for rare epithelial ovarian cancers.
    Matsuo K; Machida H; Matsuzaki S; Grubbs BH; Klar M; Roman LD; Sood AK; Gershenson DM; Wright JD
    Gynecol Oncol; 2020 Apr; 157(1):3-11. PubMed ID: 31954534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advancements in Low-Grade Serous Carcinoma of the Ovary and Peritoneum.
    Grisham RN; Chui MH
    Curr Oncol Rep; 2022 Nov; 24(11):1549-1555. PubMed ID: 35962920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review.
    Lazurko C; Linder R; Pulman K; Lennox G; Feigenberg T; Fazelzad R; May T; Zigras T
    Curr Oncol; 2023 Sep; 30(9):8159-8171. PubMed ID: 37754507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1, Ki67, and β-Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma.
    Sallum LF; Andrade L; Bastos Eloy da Costa L; Ramalho S; Ferracini AC; Natal RA; Brito ABC; Sarian LO; Derchain S
    Int J Gynecol Cancer; 2018 Mar; 28(3):437-447. PubMed ID: 29465506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Targeted Agents in Advanced and Recurrent Low-Grade Serous Ovarian Cancer: A Silver Lining in the Therapy of a Chemoresistant Disease?
    Onoprienko A; Bartl T; Grimm C; Concin N; Polterauer S
    Cancers (Basel); 2024 Sep; 16(19):. PubMed ID: 39409889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors.
    Wong KK; Bateman NW; Ng CW; Tsang YTM; Sun CS; Celestino J; Nguyen TV; Malpica A; Hillman RT; Zhang J; Futreal PA; Rojas C; Conrads KA; Hood BL; Dalgard CL; Wilkerson MD; Phippen NT; Conrads TP; Maxwell GL; Sood AK; Gershenson DM
    J Transl Med; 2022 Dec; 20(1):606. PubMed ID: 36528667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Redefining the standard of care for low-grade serous ovarian cancer.
    Manning-Geist BL; Cantor T; O'Cearbhaill RE; Grisham RN
    Clin Adv Hematol Oncol; 2024 Jun; 22(5):205-226. PubMed ID: 38805312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormone maintenance therapy for women with low-grade serous ovarian cancer in the front-line setting: A systematic review.
    Lazurko C; Clark M; Pulman K; Lennox G; May T; Fazelzad R; Gien LT; Zigras T
    Gynecol Oncol; 2021 Oct; 163(1):209-214. PubMed ID: 34325937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma.
    Pishas KI; Cowley KJ; Llaurado-Fernandez M; Kim H; Luu J; Vary R; Bowden NA; Campbell IG; Carey MS; Simpson KJ; Cheasley D
    Sci Data; 2024 Sep; 11(1):1024. PubMed ID: 39300112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma.
    Hollis RL; Elliott R; Dawson JC; Ilenkovan N; Matthews RM; Stillie LJ; Oswald AJ; Kim H; Llaurado Fernandez M; Churchman M; Porter JM; Roxburgh P; Unciti-Broceta A; Gershenson DM; Herrington CS; Carey MS; Carragher NO; Gourley C
    Gynecol Oncol; 2024 Jul; 186():42-52. PubMed ID: 38582027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective analysis of uterine involvement in low grade serous ovarian carcinoma.
    Petiot F; Descargues P; Devouassoux-Shisheboran M; You B; Rousset-Jablonski C; Raffin D; Hajri T; Gertych W; Glehen O; Philip CA; Lamblin G; Golfier F; Bolze PA
    Eur J Obstet Gynecol Reprod Biol; 2024 Mar; 294():191-197. PubMed ID: 38295707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-grade epithelial ovarian cancer: what a radiologist should know.
    Elsherif S; Javadi S; Viswanathan C; Faria S; Bhosale P
    Br J Radiol; 2019 Mar; 92(1095):20180571. PubMed ID: 30604635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian low and high grade serous carcinomas: hidden divergent features in the tumor microenvironment.
    Ciucci A; Zannoni GF; Buttarelli M; Martinelli E; Mascilini F; Petrillo M; Ferrandina G; Scambia G; Gallo D
    Oncotarget; 2016 Oct; 7(42):68033-68043. PubMed ID: 27462782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-grade serous carcinoma: molecular features and contemporary treatment strategies.
    Angarita AM; Cholakian D; Fader AN
    Expert Rev Anticancer Ther; 2015; 15(8):893-9. PubMed ID: 26040191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability.
    Shrestha R; Llaurado Fernandez M; Dawson A; Hoenisch J; Volik S; Lin YY; Anderson S; Kim H; Haegert AM; Colborne S; Wong NKY; McConeghy B; Bell RH; Brahmbhatt S; Lee CH; DiMattia GE; Le Bihan S; Morin GB; Collins CC; Carey MS
    Cancer Res; 2021 Apr; 81(7):1681-1694. PubMed ID: 33441310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.